CD39, His-Tag (Human) Recombinant

Catalog #
71284
$340 *
Size: 50 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human C39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1), encompassing amino acids 38-478. This construct contains a C-terminal His-tag (10xHis). The recombinant protein was affinity purified.

Synonyms
Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen, ENTPD1
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD39 (38-478-His)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution 

Formulation

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol 

MW
52 kDa + glycans
Amino Acids
38-478
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Specific Activity
≥3000 pmol/min/μg
Genbank #
NM_001776
UniProt #
P49961
Tag(s)
C-terminal His-tag
Background

CD39 contributes to immune regulation through the hydrolysis of ATP to AMP in the rate limiting step of extracellular adenosine production. CD39 is expressed on the surface of multiple cells of the immune system including T-cells, Natural killer cells, B-cells, dendritic cells and macrophages. In addition, high levels of CD39 expression have been associated with the tumor microenvironment (TME). Research aimed at reducing immunosuppression by CD39 activity has resulted in the study of a small molecule inhibitor, POM1, and multiple anti-CD39 antibodies selected for blocking enzymatic activity or decreasing CD39 expression. 

CD73/CD39 Immunotherapy

References
1. Deaglio, S. et al., Journal of Environmental Medicine. 2007 Jun 204(6): 1257-1265.

2. Borsellino, G. et al., Blood. 2007 Aug; 110(4):1225-1232.